CHF Solutions (NSDQ:CHFS) said yesterday it plans to expand into the post-cardiovascular surgery market, specifically with products for patients who need treatment for fluid overload and have failed diuretic therapy.
The Eden Prairie, Minn.-based company said that it sees the expansion into the post CV surgical market as a “natural next step” in its commercial expansion, as surgical patients often experience fluid overload challenges post procedure due to the administration of fluids during surgery.
“The expansion of our sales and marketing team at CHF Solutions provides us the additional resources necessary to pursue other market opportunities, and the post-cardiovascular surgery market is an excellent next foray into the market. We believe the Aquadex FlexFlow System offers a simple form of ultrafiltration that can be prescribed by any medical specialty for the treatment of volume overload in post-surgical patients who are not responding to diuretics. We look forward to continuing to partner with the medical community in the treatment of fluid overloaded patients and believe this initiative creates a significant market growth opportunity,” chair & CEO John Erb said in a prepared release.
Earlier this month, CHF Solutions said that it acquired Vasamed’s AcQtrac technology for an unspecified amount.
